Payment overview · 2025
General Payments
$14,491.68
56 reported records · 17 companies
Healthcare provider profile · identity verified
Forrest Beau Swann, MD
Allopathic & Osteopathic Physicians|Ophthalmology · WACO, TX · NPI 1407291420
Verified facts
What the public records show
CMS Open Payments records show Forrest Beau Swann, MD received $14,491.68 in general payments during 2025 across 56 reported records.
Bausch & Lomb Americas Inc. accounted for 75.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Lumigan, Miebo, Oxervate, Vyzulta, Xdemvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Lumigan by this doctor in 2024.
Alcon Vision LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rhopressa as an associated drug or biological on 1524 records involving 961 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rhopressa by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOTEMAX SM as an associated drug or biological on 92 records involving 67 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Lotemax Sm by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MIEBO as an associated drug or biological on 34133 records involving 12967 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Miebo by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLENSA as an associated drug or biological on 18 records involving 13 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Prolensa by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VYZULTA as an associated drug or biological on 10850 records involving 5317 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Vyzulta by this doctor in 2024.
Dompe US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OXERVATE as an associated drug or biological on 19540 records involving 9712 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Oxervate by this doctor in 2024.
Tarsus Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XDEMVY as an associated drug or biological on 46638 records involving 15254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xdemvy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bausch & Lomb Americas Inc. | Unresolved — no canonical attribution shown | $10,939.26 | 75.5% | 21 | 2025 |
| Johnson & Johnson Surgical Vision, Inc. | Unresolved — no canonical attribution shown | $1,836.58 | 12.7% | 4 | 2025 |
| Lumibird Medical Inc. | Unresolved — no canonical attribution shown | $340.32 | 2.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $275.22 | 1.9% | 8 | 2025 |
| BIOTISSUE HOLDINGS INC. | Unresolved — no canonical attribution shown | $208.06 | 1.4% | 2 | 2025 |
| Tarsus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $202.97 | 1.4% | 2 | 2025 |
| Sight Sciences, Inc. | Unresolved — no canonical attribution shown | $167.14 | 1.1% | 5 | 2025 |
| LENSAR, Inc. | Unresolved — no canonical attribution shown | $98.87 | 0.7% | 2 | 2025 |
| RxSight Inc | Unresolved — no canonical attribution shown | $97.62 | 0.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $89.70 | 0.6% | 3 | 2025 |
| Ocular Therapeutix, Inc. | Unresolved — no canonical attribution shown | $89.22 | 0.6% | 1 | 2025 |
| CorMedix Inc. | Unresolved — no canonical attribution shown | $27.85 | 0.2% | 1 | 2025 |
| Dompe US, Inc. | Unresolved — no canonical attribution shown | $26.83 | 0.2% | 1 | 2025 |
| Alcon Vision LLC | Unresolved — no canonical attribution shown | $25.61 | 0.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.60 | 0.2% | 1 | 2025 |
| Oyster Point Pharma, Inc. | Unresolved — no canonical attribution shown | $22.69 | 0.2% | 1 | 2025 |
| Thea Pharma Inc. | Unresolved — no canonical attribution shown | $20.14 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $7,715.00 | 3 |
| Compensation for serving as faculty or as a speaker for a medical education program | $3,400.00 | 1 |
| Food and Beverage | $2,990.04 | 49 |
| Travel and Lodging | $386.64 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| enVista MX60 IOL Normalized: envista mx60 iol |
Device | Bausch & Lomb Americas Inc. | $9,681.22 | 6 | 2025 |
Source payment records
|
|||||
| STELLARIS ELITE Normalized: stellaris elite |
Device | Bausch & Lomb Americas Inc. | $6,325.00 | 2 | 2025 |
Source payment records
|
|||||
| Crystalens Accommodating IOL (AT-52AO) Normalized: crystalens accommodating iol at 52ao |
Device | Bausch & Lomb Americas Inc. | $5,750.00 | 1 | 2025 |
Source payment records
|
|||||
| Trulign IOL Normalized: trulign iol |
Device | Bausch & Lomb Americas Inc. | $5,750.00 | 1 | 2025 |
Source payment records
|
|||||
| Tecnis Simplicity Normalized: tecnis simplicity |
Device | Johnson & Johnson Surgical Vision, Inc. | $1,534.52 | 2 | 2025 |
Source payment records
|
|||||
| Tecnis IOL Normalized: tecnis iol |
Device | Johnson & Johnson Surgical Vision, Inc. | $1,390.00 | 1 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $275.22 | 8 | 2025 |
Source payment records
|
|||||
| MIEBO Normalized: miebo |
Drug | Bausch & Lomb Americas Inc. | $239.37 | 3 | 2025 |
Source payment records
|
|||||
| XDEMVY Normalized: xdemvy |
Drug | Tarsus Pharmaceuticals, Inc. | $202.97 | 2 | 2025 |
Source payment records
|
|||||
| enVista Envy IOL Normalized: envista envy iol |
Device | Bausch & Lomb Americas Inc. | $188.18 | 4 | 2025 |
Source payment records
|
|||||
| OMNI SURGICAL SYSTEM Normalized: omni surgical system |
Device | Sight Sciences, Inc. | $167.14 | 5 | 2025 |
Source payment records
|
|||||
| VERITAS Vision System Normalized: veritas vision system |
Device | Johnson & Johnson Surgical Vision, Inc. | $165.00 | 1 | 2025 |
Source payment records
|
|||||
| XIIDRA Normalized: xiidra |
Drug | Bausch & Lomb Americas Inc. | $164.54 | 1 | 2025 |
Source payment records
|
|||||
| CATALYS SYSTEM Normalized: catalys system |
Device | Johnson & Johnson Surgical Vision, Inc. | $137.06 | 1 | 2025 |
Source payment records
|
|||||
| SION SURGICAL INSTRUMENT Normalized: sion surgical instrument |
Device | Sight Sciences, Inc. | $130.91 | 1 | 2025 |
Source payment records
|
|||||
| VYZULTA Normalized: vyzulta |
Drug | Bausch & Lomb Americas Inc. | $110.35 | 5 | 2025 |
Source payment records
|
|||||
| Akreos AO IOL Normalized: akreos ao iol |
Device | Bausch & Lomb Americas Inc. | $101.16 | 1 | 2025 |
Source payment records
|
|||||
| LENSAR LASER SYSTEM Normalized: lensar laser system |
Device | LENSAR, Inc. | $98.87 | 2 | 2025 |
Source payment records
|
|||||
| LIGHT ADJUSTABLE LENS (LAL) Normalized: light adjustable lens lal |
Device | RxSight Inc | $97.62 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT CONTACT LENS Normalized: rxsight contact lens |
Device | RxSight Inc | $97.62 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT INJECTOR CARTRIDGE Normalized: rxsight injector cartridge |
Device | RxSight Inc | $97.62 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT INJECTOR HANDPIECE Normalized: rxsight injector handpiece |
Device | RxSight Inc | $97.62 | 1 | 2025 |
Source payment records
|
|||||
| RXSIGHT LIGHT DELIVERY DEVICE (LDD) Normalized: rxsight light delivery device ldd |
Device | RxSight Inc | $97.62 | 1 | 2025 |
Source payment records
|
|||||
| DEXTENZA Normalized: dextenza |
Drug | Ocular Therapeutix, Inc. | $89.22 | 1 | 2025 |
Source payment records
|
|||||
| LUMIGAN Normalized: lumigan |
Drug | ABBVIE INC. | $58.06 | 2 | 2025 |
Source payment records
|
|||||
| DURYSTA Normalized: durysta |
Drug | ABBVIE INC. | $31.64 | 1 | 2025 |
Source payment records
|
|||||
| DEFENCATH Normalized: defencath |
Drug | CorMedix Inc. | $27.85 | 1 | 2025 |
Source payment records
|
|||||
| OXERVATE Normalized: oxervate |
Drug | Dompe US, Inc. | $26.83 | 1 | 2025 |
Source payment records
|
|||||
| TRYPTYR Normalized: tryptyr |
Drug | Alcon Vision LLC | $25.61 | 1 | 2025 |
Source payment records
|
|||||
| Vitrakvi Normalized: vitrakvi |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $23.60 | 1 | 2025 |
Source payment records
|
|||||
| RYZUMVI Normalized: ryzumvi |
Drug | Oyster Point Pharma, Inc. | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| TYRVAYA Normalized: tyrvaya |
Drug | Oyster Point Pharma, Inc. | $22.69 | 1 | 2025 |
Source payment records
|
|||||
| IYUZEH Normalized: iyuzeh |
Drug | Thea Pharma Inc. | $20.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LUMIGAN lumigan |
2025 | Lumigan | 2024 | 32 | exact normalized | Medicare Part D |
| MIEBO miebo |
2025 | Miebo | 2024 | 150 | exact normalized | Medicare Part D |
| OXERVATE oxervate |
2025 | Oxervate | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VYZULTA vyzulta |
2025 | Vyzulta | 2024 | 53 | exact normalized | Medicare Part D |
| XDEMVY xdemvy |
2025 | Xdemvy | 2024 | 13 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| Alcon Vision LLC Exact reporting entity; no affiliate inference |
2025 | Rhopressa open payments reported associated product |
CMS Open Payments — General Payments 1524 supporting records · 961 recipient NPIs · example record 1207357314 |
Rhopressa · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | LOTEMAX SM open payments reported associated product |
CMS Open Payments — General Payments 92 supporting records · 67 recipient NPIs · example record 1254732081 |
Lotemax Sm · 2024 Exact normalized brand match · 1 Part D row |
80 | 44 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | MIEBO open payments reported associated product |
CMS Open Payments — General Payments 34133 supporting records · 12967 recipient NPIs · example record 1254730224 |
Miebo · 2024 Exact normalized brand match · 1 Part D row |
150 | 80 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | PROLENSA open payments reported associated product |
CMS Open Payments — General Payments 18 supporting records · 13 recipient NPIs · example record 1254766966 |
Prolensa · 2024 Exact normalized brand match · 1 Part D row |
219 | 144 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | VYZULTA open payments reported associated product |
CMS Open Payments — General Payments 10850 supporting records · 5317 recipient NPIs · example record 1254730226 |
Vyzulta · 2024 Exact normalized brand match · 1 Part D row |
53 | 16 |
| Dompe US, Inc. Exact reporting entity; no affiliate inference |
2025 | OXERVATE open payments reported associated product |
CMS Open Payments — General Payments 19540 supporting records · 9712 recipient NPIs · example record 1248849978 |
Oxervate · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Tarsus Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | XDEMVY open payments reported associated product |
CMS Open Payments — General Payments 46638 supporting records · 15254 recipient NPIs · example record 1233825434 |
Xdemvy · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Ofloxacin | Ofloxacin | 712 | 495 |
| Latanoprost | Latanoprost | 589 | 131 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 436 | 124 |
| Prednisolone Acetate | Prednisolone Acetate | 378 | 236 |
| Prolensa | Bromfenac Sodium | 219 | 144 |
| Brimonidine Tartrate | Brimonidine Tartrate | 180 | 53 |
| Miebo | Perfluorohexyloctane/Pf | 150 | 80 |
| Timolol Maleate | Timolol Maleate | 99 | 24 |
| Lotemax Sm | Loteprednol Etabonate | 80 | 44 |
| Bromfenac Sodium | Bromfenac Sodium | 79 | 52 |
| Acyclovir | Acyclovir | 72 | 24 |
| Dorzolamide Hcl | Dorzolamide Hcl | 55 | 19 |
| Vyzulta | Latanoprostene Bunod | 53 | 16 |
| Alprazolam | Alprazolam | 47 | 34 |
| Oxervate | Cenegermin-Bkbj | 34 | suppressed |
| Lumigan | Bimatoprost | 32 | 12 |
| Restasis | Cyclosporine | 30 | suppressed |
| Erythromycin | Erythromycin Base | 26 | 22 |
| Ilevro | Nepafenac | 24 | 18 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 23 | 22 |
| Trifluridine | Trifluridine | 22 | suppressed |
| Alphagan P | Brimonidine Tartrate | 16 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 16 | suppressed |
| Rhopressa | Netarsudil Mesylate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Xdemvy | Lotilaner | 13 | 13 |
| Zioptan | Tafluprost/Pf | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14,491.68 · 56 records | Bausch & Lomb Americas Inc. | Akreos AO IOL, CATALYS SYSTEM, Crystalens Accommodating IOL (AT-52AO), DEFENCATH, DEXTENZA, DURYSTA, IYUZEH, LENSAR LASER SYSTEM, LIGHT ADJUSTABLE LENS (LAL), LUMIGAN, MIEBO, OMNI SURGICAL SYSTEM, OXERVATE, RXSIGHT CONTACT LENS, RXSIGHT INJECTOR CARTRIDGE, RXSIGHT INJECTOR HANDPIECE, RXSIGHT LIGHT DELIVERY DEVICE (LDD), RYZUMVI, SION SURGICAL INSTRUMENT, STELLARIS ELITE, TEPEZZA, TRYPTYR, TYRVAYA, Tecnis IOL, Tecnis Simplicity, Trulign IOL, VERITAS Vision System, VYZULTA, Vitrakvi, XDEMVY, XIIDRA, enVista Envy IOL, enVista MX60 IOL | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Lumigan play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error